The potential of breast cancer screening in Europe
Currently, all European countries offer some form of breast cancer screening. Nevertheless, disparities exist in the status of implementation, attendance and the extent of opportunistic screening. As a result, breast cancer screening has not yet reached its full potential. We examined how many breas...
Uloženo v:
| Vydáno v: | International journal of cancer Ročník 148; číslo 2; s. 406 - 418 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Hoboken, USA
John Wiley & Sons, Inc
15.01.2021
Wiley Subscription Services, Inc |
| Témata: | |
| ISSN: | 0020-7136, 1097-0215, 1097-0215 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Currently, all European countries offer some form of breast cancer screening. Nevertheless, disparities exist in the status of implementation, attendance and the extent of opportunistic screening. As a result, breast cancer screening has not yet reached its full potential. We examined how many breast cancer deaths could be prevented if all European countries would biennially screen all women aged 50 to 69 for breast cancer. We calculated the number of breast cancer deaths already prevented due to screening as well as the number of breast cancer deaths which could be additionally prevented if the total examination coverage (organised plus opportunistic) would reach 100%. The calculations are based on total examination coverage in women aged 50 to 69, the annual number of breast cancer deaths for women aged 50 to 74 and the maximal possible mortality reduction from breast cancer, assuming similar effectiveness of organised and opportunistic screening. The total examination coverage ranged from 49% (East), 62% (West), 64% (North) to 69% (South). Yearly 21 680 breast cancer deaths have already been prevented due to mammography screening. If all countries would reach 100% examination coverage, 12 434 additional breast cancer deaths could be prevented annually, with the biggest potential in Eastern Europe. With maximum coverage, 23% of their breast cancer deaths could be additionally prevented, while in Western Europe it could be 21%, in Southern Europe 15% and in Northern Europe 9%. Our study illustrates that by further optimising screening coverage, the number of breast cancer deaths in Europe can be lowered substantially.
What's new?
Breast cancer is the leading cause of death among European women. Although screening for breast cancer is available in all European countries, not all eligible women aged 50‐69 get screened. Here, the authors calculated how many deaths could be prevented if screening coverage reached 100%, considering both organized and opportunistic screening. Already, screening prevents 21 680 deaths per year, and if all countries reached full examination coverage, an additional 12 434 deaths per year could be prevented across Europe. |
|---|---|
| AbstractList | Currently, all European countries offer some form of breast cancer screening. Nevertheless, disparities exist in the status of implementation, attendance and the extent of opportunistic screening. As a result, breast cancer screening has not yet reached its full potential. We examined how many breast cancer deaths could be prevented if all European countries would biennially screen all women aged 50 to 69 for breast cancer. We calculated the number of breast cancer deaths already prevented due to screening as well as the number of breast cancer deaths which could be additionally prevented if the total examination coverage (organised plus opportunistic) would reach 100%. The calculations are based on total examination coverage in women aged 50 to 69, the annual number of breast cancer deaths for women aged 50 to 74 and the maximal possible mortality reduction from breast cancer, assuming similar effectiveness of organised and opportunistic screening. The total examination coverage ranged from 49% (East), 62% (West), 64% (North) to 69% (South). Yearly 21 680 breast cancer deaths have already been prevented due to mammography screening. If all countries would reach 100% examination coverage, 12 434 additional breast cancer deaths could be prevented annually, with the biggest potential in Eastern Europe. With maximum coverage, 23% of their breast cancer deaths could be additionally prevented, while in Western Europe it could be 21%, in Southern Europe 15% and in Northern Europe 9%. Our study illustrates that by further optimising screening coverage, the number of breast cancer deaths in Europe can be lowered substantially.Currently, all European countries offer some form of breast cancer screening. Nevertheless, disparities exist in the status of implementation, attendance and the extent of opportunistic screening. As a result, breast cancer screening has not yet reached its full potential. We examined how many breast cancer deaths could be prevented if all European countries would biennially screen all women aged 50 to 69 for breast cancer. We calculated the number of breast cancer deaths already prevented due to screening as well as the number of breast cancer deaths which could be additionally prevented if the total examination coverage (organised plus opportunistic) would reach 100%. The calculations are based on total examination coverage in women aged 50 to 69, the annual number of breast cancer deaths for women aged 50 to 74 and the maximal possible mortality reduction from breast cancer, assuming similar effectiveness of organised and opportunistic screening. The total examination coverage ranged from 49% (East), 62% (West), 64% (North) to 69% (South). Yearly 21 680 breast cancer deaths have already been prevented due to mammography screening. If all countries would reach 100% examination coverage, 12 434 additional breast cancer deaths could be prevented annually, with the biggest potential in Eastern Europe. With maximum coverage, 23% of their breast cancer deaths could be additionally prevented, while in Western Europe it could be 21%, in Southern Europe 15% and in Northern Europe 9%. Our study illustrates that by further optimising screening coverage, the number of breast cancer deaths in Europe can be lowered substantially. Currently, all European countries offer some form of breast cancer screening. Nevertheless, disparities exist in the status of implementation, attendance and the extent of opportunistic screening. As a result, breast cancer screening has not yet reached its full potential. We examined how many breast cancer deaths could be prevented if all European countries would biennially screen all women aged 50 to 69 for breast cancer. We calculated the number of breast cancer deaths already prevented due to screening as well as the number of breast cancer deaths which could be additionally prevented if the total examination coverage (organised plus opportunistic) would reach 100%. The calculations are based on total examination coverage in women aged 50 to 69, the annual number of breast cancer deaths for women aged 50 to 74 and the maximal possible mortality reduction from breast cancer, assuming similar effectiveness of organised and opportunistic screening. The total examination coverage ranged from 49% (East), 62% (West), 64% (North) to 69% (South). Yearly 21 680 breast cancer deaths have already been prevented due to mammography screening. If all countries would reach 100% examination coverage, 12 434 additional breast cancer deaths could be prevented annually, with the biggest potential in Eastern Europe. With maximum coverage, 23% of their breast cancer deaths could be additionally prevented, while in Western Europe it could be 21%, in Southern Europe 15% and in Northern Europe 9%. Our study illustrates that by further optimising screening coverage, the number of breast cancer deaths in Europe can be lowered substantially. What's new? Breast cancer is the leading cause of death among European women. Although screening for breast cancer is available in all European countries, not all eligible women aged 50‐69 get screened. Here, the authors calculated how many deaths could be prevented if screening coverage reached 100%, considering both organized and opportunistic screening. Already, screening prevents 21 680 deaths per year, and if all countries reached full examination coverage, an additional 12 434 deaths per year could be prevented across Europe. Currently, all European countries offer some form of breast cancer screening. Nevertheless, disparities exist in the status of implementation, attendance and the extent of opportunistic screening. As a result, breast cancer screening has not yet reached its full potential. We examined how many breast cancer deaths could be prevented if all European countries would biennially screen all women aged 50 to 69 for breast cancer. We calculated the number of breast cancer deaths already prevented due to screening as well as the number of breast cancer deaths which could be additionally prevented if the total examination coverage (organised plus opportunistic) would reach 100%. The calculations are based on total examination coverage in women aged 50 to 69, the annual number of breast cancer deaths for women aged 50 to 74 and the maximal possible mortality reduction from breast cancer, assuming similar effectiveness of organised and opportunistic screening. The total examination coverage ranged from 49% (East), 62% (West), 64% (North) to 69% (South). Yearly 21 680 breast cancer deaths have already been prevented due to mammography screening. If all countries would reach 100% examination coverage, 12 434 additional breast cancer deaths could be prevented annually, with the biggest potential in Eastern Europe. With maximum coverage, 23% of their breast cancer deaths could be additionally prevented, while in Western Europe it could be 21%, in Southern Europe 15% and in Northern Europe 9%. Our study illustrates that by further optimising screening coverage, the number of breast cancer deaths in Europe can be lowered substantially. |
| Author | Heijnsdijk, Eveline A. M. Ravesteyn, Nicolien T. Zielonke, Nadine McKee, Martin Veerus, Piret Koning, Harry J. Kregting, Lindy M. Kok, Inge M. C. M. Heinävaara, Sirpa |
| AuthorAffiliation | The EU-TOPIA collaborators are listed in the Appendix |
| AuthorAffiliation_xml | – name: The EU-TOPIA collaborators are listed in the Appendix – name: 2 National Institute for Health Development Tallinn Estonia – name: 1 Department of Public Health Erasmus MC, University Medical Center Rotterdam Rotterdam The Netherlands – name: 5 The EU‐TOPIA collaborators are listed in the Appendix – name: 4 London School of Hygiene and Tropical Medicine London UK – name: 3 Finnish Cancer Registry Helsinki Finland |
| Author_xml | – sequence: 1 givenname: Nadine orcidid: 0000-0001-6148-2371 surname: Zielonke fullname: Zielonke, Nadine email: n.zielonke@erasmusmc.nl organization: Erasmus MC, University Medical Center Rotterdam – sequence: 2 givenname: Lindy M. surname: Kregting fullname: Kregting, Lindy M. organization: Erasmus MC, University Medical Center Rotterdam – sequence: 3 givenname: Eveline A. M. orcidid: 0000-0002-4890-6069 surname: Heijnsdijk fullname: Heijnsdijk, Eveline A. M. organization: Erasmus MC, University Medical Center Rotterdam – sequence: 4 givenname: Piret surname: Veerus fullname: Veerus, Piret organization: National Institute for Health Development – sequence: 5 givenname: Sirpa surname: Heinävaara fullname: Heinävaara, Sirpa organization: Finnish Cancer Registry – sequence: 6 givenname: Martin surname: McKee fullname: McKee, Martin organization: London School of Hygiene and Tropical Medicine – sequence: 7 givenname: Inge M. C. M. orcidid: 0000-0002-9419-0452 surname: Kok fullname: Kok, Inge M. C. M. organization: Erasmus MC, University Medical Center Rotterdam – sequence: 8 givenname: Harry J. orcidid: 0000-0003-4682-3646 surname: Koning fullname: Koning, Harry J. organization: Erasmus MC, University Medical Center Rotterdam – sequence: 9 givenname: Nicolien T. surname: Ravesteyn fullname: Ravesteyn, Nicolien T. organization: Erasmus MC, University Medical Center Rotterdam |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32683673$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kU1LAzEYhIMoWqsH_4AseNHDaj43uxdBip8IXuo5pOm7bco2qcmu4r832la06CmHeWaYvLOPtp13gNARwecEY3phZ-acMYr5FuoRXMkcUyK2US9pOJeEFXtoP8YZxoQIzHfRHqNFyQrJeogOp5AtfAuutbrJfJ2NAujYZkY7AyGLJgA46yaZddl1F_wCDtBOrZsIh6u3j55vroeDu_zx6fZ-cPWYG84Zz43RBR3rmpSGcVMZKnk11pRgAWXqVxMmaMnrSozFiEFRSD7ClDJpoGaSJrmPLpe5i240h7FJFYNu1CLYuQ7vymurfivOTtXEvyopBReYpYDTVUDwLx3EVs1tNNA02oHvoqKcClExUfKEnmygM98Fl76XqIITUZa4TNTxz0bfVdbnTMDFEjDBxxigVsa2urX-s6BtFMHqczCVBlNfgyXH2YZjHfoXu0p_sw28_w-q-4fB0vEBGH2ieA |
| CitedBy_id | crossref_primary_10_3389_fpubh_2022_1071317 crossref_primary_10_7759_cureus_60834 crossref_primary_10_1007_s00403_023_02753_9 crossref_primary_10_1016_j_jhealeco_2023_102803 crossref_primary_10_3389_fpubh_2025_1500098 crossref_primary_10_3390_ijerph192315785 crossref_primary_10_1016_j_radi_2023_06_010 crossref_primary_10_3390_healthcare12151468 crossref_primary_10_3390_life15010092 crossref_primary_10_1186_s12916_023_03217_7 crossref_primary_10_1002_ijc_34494 crossref_primary_10_3390_healthcare11222934 crossref_primary_10_1016_j_canep_2022_102312 crossref_primary_10_3390_cancers14153734 crossref_primary_10_3390_bios13030348 crossref_primary_10_1186_s12889_023_16677_6 crossref_primary_10_1177_09691413231199583 crossref_primary_10_3390_jcm13164610 crossref_primary_10_1177_10732748241266491 crossref_primary_10_1177_09691413221101807 crossref_primary_10_1016_j_ejogrb_2023_08_385 crossref_primary_10_1259_bjr_20220880 crossref_primary_10_3390_cancers13071578 crossref_primary_10_3390_cancers13174374 crossref_primary_10_1002_fsn3_70632 crossref_primary_10_1186_s12885_023_10890_7 crossref_primary_10_1097_MOU_0000000000001257 crossref_primary_10_1016_j_ejrad_2024_111784 crossref_primary_10_1093_eurpub_ckad206 crossref_primary_10_3390_clinpract14020036 crossref_primary_10_1007_s10549_024_07296_9 crossref_primary_10_1186_s12889_022_14685_6 crossref_primary_10_1093_jbi_wbae091 crossref_primary_10_1186_s12889_024_17876_5 crossref_primary_10_1186_s13690_023_01165_5 crossref_primary_10_1016_S1470_2045_22_00540_X crossref_primary_10_1186_s12885_024_13346_8 crossref_primary_10_1177_09691413231153568 crossref_primary_10_1016_j_canep_2025_102898 crossref_primary_10_1002_cam4_5231 crossref_primary_10_1016_j_canep_2022_102214 crossref_primary_10_3390_medicina60071023 crossref_primary_10_1016_j_jcpo_2024_100499 crossref_primary_10_1016_j_jcpo_2024_100531 crossref_primary_10_2147_RMHP_S391534 crossref_primary_10_3390_ijms23031672 crossref_primary_10_1371_journal_pmed_1004431 crossref_primary_10_3390_cancers15010069 crossref_primary_10_1186_s13561_025_00628_5 crossref_primary_10_1016_j_canep_2022_102270 crossref_primary_10_1007_s00330_023_09973_7 crossref_primary_10_3390_ijerph21081006 crossref_primary_10_1016_j_bspc_2023_104997 crossref_primary_10_1007_s11042_024_18775_y crossref_primary_10_3390_cancers13133360 crossref_primary_10_3389_fpubh_2025_1535564 crossref_primary_10_1016_j_crad_2023_10_030 crossref_primary_10_7759_cureus_52434 crossref_primary_10_1177_00469580211060254 crossref_primary_10_3390_cancers15102704 crossref_primary_10_2196_65974 crossref_primary_10_1002_mp_18061 crossref_primary_10_1002_ijc_35173 |
| Cites_doi | 10.1016/j.healthpol.2018.08.003 10.1002/ijc.27609 10.1136/bmj.g3701 10.1258/jms.2012.012078 10.1016/j.pec.2012.08.003 10.1016/j.ejca.2018.07.005 10.1258/jms.2012.012079 10.1158/1055-9965.EPI-15-0803 10.7326/M15-0969 10.1038/bjc.2013.177 10.1056/NEJMsr1504363 10.1093/annonc/mdn770 10.1002/ijc.31043 10.1258/jms.2008.007055 10.1093/jnci/djn224 10.1016/S0140-6736(12)62082-0 10.1016/j.breast.2014.03.002 10.1038/sj.bjc.6604532 10.1186/bcr3090 10.1038/bjc.2016.415 10.1016/j.ejca.2008.09.015 10.1097/MD.0000000000005684 10.1016/j.healthpol.2018.08.004 10.1093/annonc/mdm481 10.1148/radiol.11110469 10.1016/j.ejca.2019.12.010 10.1258/jms.2011.010086 10.1186/1741-7015-10-163 10.3310/hta4140 10.1038/bjc.2016.68 10.1186/1471-2458-13-464 |
| ContentType | Journal Article |
| Copyright | 2020 The Authors. published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control. 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control. 2020. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2020 The Authors. published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control. – notice: 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control. – notice: 2020. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | the EU‐TOPIA collaborators EU-TOPIA collaborators |
| CorporateAuthor_xml | – name: the EU‐TOPIA collaborators – name: EU-TOPIA collaborators |
| DBID | 24P AAYXX CITATION NPM 7T5 7TO 7U9 H94 K9. 7X8 5PM |
| DOI | 10.1002/ijc.33204 |
| DatabaseName | Wiley Online Library Open Access CrossRef PubMed Immunology Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed CrossRef AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Zielonke et al |
| EISSN | 1097-0215 |
| EndPage | 418 |
| ExternalDocumentID | PMC7754503 32683673 10_1002_ijc_33204 IJC33204 |
| Genre | article Journal Article |
| GeographicLocations | Europe |
| GeographicLocations_xml | – name: Europe |
| GrantInformation_xml | – fundername: Horizon 2020 Framework Programme funderid: 634753 – fundername: Horizon 2020 Framework Programme grantid: 634753 – fundername: ; grantid: 634753 |
| GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RX1 RYL SUPJJ TEORI UB1 UDS V2E V8K V9Y W2D W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WIN WJL WOHZO WQJ WRC WUP WVDHM WWO WXI WXSBR XG1 XPP XV2 ZZTAW ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGXDD AGYGG AIDQK AIDYY CITATION O8X NPM 7T5 7TO 7U9 H94 K9. 7X8 5PM AASGY |
| ID | FETCH-LOGICAL-c4434-cca62daf18c34c9c2749da2105e8021f135284f95d5b3e6674b02237cef372f13 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 73 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000553429100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0020-7136 1097-0215 |
| IngestDate | Tue Nov 04 01:58:07 EST 2025 Fri Jul 11 09:20:35 EDT 2025 Sat Nov 29 14:34:58 EST 2025 Thu Apr 03 06:57:11 EDT 2025 Sat Nov 29 03:46:32 EST 2025 Tue Nov 18 22:13:20 EST 2025 Wed Jan 22 16:31:22 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | screening guidelines screening coverage breast cancer screening breast cancer mortality reduction breast cancer mortality |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of Union for International Cancer Control. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4434-cca62daf18c34c9c2749da2105e8021f135284f95d5b3e6674b02237cef372f13 |
| Notes | Funding information Horizon 2020 Framework Programme, Grant/Award Number: 634753 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Funding information Horizon 2020 Framework Programme, Grant/Award Number: 634753 |
| ORCID | 0000-0002-9419-0452 0000-0002-4890-6069 0000-0001-6148-2371 0000-0003-4682-3646 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.33204 |
| PMID | 32683673 |
| PQID | 2464158808 |
| PQPubID | 105430 |
| PageCount | 13 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7754503 proquest_miscellaneous_2425593584 proquest_journals_2464158808 pubmed_primary_32683673 crossref_citationtrail_10_1002_ijc_33204 crossref_primary_10_1002_ijc_33204 wiley_primary_10_1002_ijc_33204_IJC33204 |
| PublicationCentury | 2000 |
| PublicationDate | 15 January 2021 |
| PublicationDateYYYYMMDD | 2021-01-15 |
| PublicationDate_xml | – month: 01 year: 2021 text: 15 January 2021 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | Hoboken, USA |
| PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Hoboken |
| PublicationTitle | International journal of cancer |
| PublicationTitleAlternate | Int J Cancer |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
| References | 2018; 142 2009; 45 2018; 122 2009; 20 2013; 108 2000; 4 2008; 19 2018; 103 2020; 127 2008; 15 2012; 19 2008; 99 2012; 14 2008; 100 2013; 381 2016; 15 2011; 18 2016; 164 2014; 23 2012; 10 2017; 116 2015; 372 2014; 348 2017; 96 2013; 13 2013; 132 2016; 114 2011; 260 2012; 89 2016; 25 e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 IARC Working Group (e_1_2_9_24_1) 2016 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 e_1_2_9_29_1 |
| References_xml | – volume: 122 start-page: 1198 issue: 11 year: 2018 end-page: 1205 article-title: A health systems approach to identifying barriers to breast cancer screening programmes. Methodology and application in six European countries publication-title: Health Policy – volume: 132 start-page: 208 issue: 1 year: 2013 end-page: 214 article-title: Breast cancer mortality in Norway after the introduction of mammography screening publication-title: Int J Cancer – volume: 20 start-page: 1199 issue: 7 year: 2009 end-page: 1202 article-title: Effectiveness of organised versus opportunistic mammography screening publication-title: Ann Oncol – volume: 122 start-page: 1190 issue: 11 year: 2018 end-page: 1197 article-title: Identifying the barriers to effective breast, cervical and colorectal cancer screening in thirty one European countries using the Barriers to Effective Screening Tool (BEST) publication-title: Health Policy – volume: 23 start-page: 439 issue: 4 year: 2014 end-page: 444 article-title: Breast cancer screening halves the risk of breast cancer death: a case‐referent study publication-title: Breast – volume: 89 start-page: 353 issue: 2 year: 2012 end-page: 359 article-title: Do women make an informed choice about participating in breast cancer screening? A survey among women invited for a first mammography screening examination publication-title: Patient Educ Couns – volume: 10 start-page: 163 year: 2012 article-title: Breast cancer screening: evidence of benefit depends on the method used publication-title: BMC Med – volume: 381 start-page: 1125 issue: 9872 year: 2013 end-page: 1134 article-title: The unequal health of Europeans: successes and failures of policies publication-title: Lancet – volume: 348 year: 2014 article-title: Modern mammography screening and breast cancer mortality: population study publication-title: BMJ – volume: 15 year: 2016 – volume: 96 issue: 3 year: 2017 article-title: Clarifying the debate on population‐based screening for breast cancer with mammography: a systematic review of randomized controlled trials on mammography with Bayesian meta‐analysis and causal model publication-title: Medicine – volume: 164 start-page: 244 issue: 4 year: 2016 end-page: 255 article-title: Effectiveness of breast cancer screening: systematic review and meta‐analysisto update the 2009 U.S. Preventive Services Task Force recommendation publication-title: Ann Intern Med – volume: 142 start-page: 44 issue: 1 year: 2018 end-page: 56 article-title: Status of implementation and organization of cancer screening in the European Union Member States‐Summary results from the second European screening report publication-title: Int J Cancer – volume: 108 start-page: 2205 issue: 11 year: 2013 end-page: 2240 article-title: The benefits and harms of breast cancer screening: an independent review publication-title: Br J Cancer – volume: 372 start-page: 2353 issue: 24 year: 2015 end-page: 2358 article-title: Breast‐cancer screening—viewpoint of the IARC Working Group publication-title: N Engl J Med – volume: 25 start-page: 455 issue: 3 year: 2016 end-page: 462 article-title: Impact of screening on breast cancer mortality: the UK program 20 years on publication-title: Cancer Epidemiol Biomarkers Prev – volume: 103 start-page: 356 year: 2018 end-page: 387 article-title: Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018 publication-title: Eur J Cancer – volume: 19 start-page: 14 issue: suppl 1 year: 2012 end-page: 25 article-title: The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies publication-title: J Med Screen – volume: 45 start-page: 127 issue: 1 year: 2009 end-page: 138 article-title: Cost‐effectiveness of opportunistic versus organised mammography screening in Switzerland publication-title: Eur J Cancer – volume: 13 start-page: 464 year: 2013 article-title: Methods to increase participation in organised screening programs: a systematic review publication-title: BMC Public Health – volume: 116 start-page: 246 issue: 2 year: 2017 end-page: 252 article-title: Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual‐level cohort study publication-title: Br J Cancer – volume: 127 start-page: 191 year: 2020 end-page: 206 article-title: Evidence for reducing cancer specific mortality due to screening for breast cancer in Europe: a systematic review publication-title: Eur J Cancer – volume: 260 start-page: 658 issue: 3 year: 2011 end-page: 663 article-title: Swedish two‐county trial: impact of mammographic screening on breast cancer mortality during 3 decades publication-title: Radiology – volume: 4 start-page: i issue: 14 year: 2000 end-page: vii article-title: The determinants of screening uptake and interventions for increasing uptake: a systematic review publication-title: Health Technol Assess – volume: 100 start-page: 1082 issue: 15 year: 2008 end-page: 1091 article-title: Comparing screening mammography for early breast cancer detection in Vermont and Norway publication-title: J Natl Cancer Inst – volume: 18 start-page: 87 issue: 2 year: 2011 end-page: 90 article-title: Narrowing the equity gap: the impact of organized versus opportunistic cancer screening in Catalonia (Spain) publication-title: J Med Screen – volume: 14 issue: 1 year: 2012 article-title: Balancing harms and benefits of service mammography screening programs: a cohort study publication-title: Breast Cancer Res – volume: 19 start-page: 614 issue: 4 year: 2008 end-page: 622 article-title: European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition—summary document publication-title: Ann Oncol – volume: 99 start-page: 423 issue: 3 year: 2008 end-page: 427 article-title: Effectiveness of service screening: a case‐control study to assess breast cancer mortality reduction publication-title: Br J Cancer – volume: 19 start-page: 26 issue: suppl 1 year: 2012 end-page: 32 article-title: The impact of mammographic screening on breast cancer mortality in Europe: a review of trend studies publication-title: J Med Screen – volume: 114 start-page: 1038 year: 2016 end-page: 1044 article-title: Impact of organised mammography screening on breast cancer mortality in a case‐control and cohort study publication-title: Br J Cancer – volume: 15 start-page: 23 issue: 1 year: 2008 end-page: 26 article-title: Performance of systematic and non‐systematic (‘opportunistic’) screening mammography: a comparative study from Denmark publication-title: J Med Screen – ident: e_1_2_9_38_1 doi: 10.1016/j.healthpol.2018.08.003 – ident: e_1_2_9_11_1 doi: 10.1002/ijc.27609 – ident: e_1_2_9_9_1 doi: 10.1136/bmj.g3701 – ident: e_1_2_9_6_1 doi: 10.1258/jms.2012.012078 – ident: e_1_2_9_32_1 doi: 10.1016/j.pec.2012.08.003 – ident: e_1_2_9_3_1 doi: 10.1016/j.ejca.2018.07.005 – ident: e_1_2_9_7_1 doi: 10.1258/jms.2012.012079 – ident: e_1_2_9_17_1 – ident: e_1_2_9_14_1 doi: 10.1158/1055-9965.EPI-15-0803 – ident: e_1_2_9_5_1 doi: 10.7326/M15-0969 – ident: e_1_2_9_21_1 doi: 10.1038/bjc.2013.177 – ident: e_1_2_9_34_1 doi: 10.1056/NEJMsr1504363 – ident: e_1_2_9_28_1 doi: 10.1093/annonc/mdn770 – ident: e_1_2_9_19_1 doi: 10.1002/ijc.31043 – ident: e_1_2_9_4_1 – ident: e_1_2_9_26_1 doi: 10.1258/jms.2008.007055 – ident: e_1_2_9_2_1 – ident: e_1_2_9_27_1 doi: 10.1093/jnci/djn224 – ident: e_1_2_9_35_1 doi: 10.1016/S0140-6736(12)62082-0 – ident: e_1_2_9_13_1 doi: 10.1016/j.breast.2014.03.002 – ident: e_1_2_9_25_1 doi: 10.1038/sj.bjc.6604532 – ident: e_1_2_9_12_1 doi: 10.1186/bcr3090 – ident: e_1_2_9_15_1 doi: 10.1038/bjc.2016.415 – ident: e_1_2_9_30_1 doi: 10.1016/j.ejca.2008.09.015 – ident: e_1_2_9_18_1 – ident: e_1_2_9_22_1 – ident: e_1_2_9_23_1 – ident: e_1_2_9_20_1 doi: 10.1097/MD.0000000000005684 – ident: e_1_2_9_39_1 doi: 10.1016/j.healthpol.2018.08.004 – ident: e_1_2_9_31_1 doi: 10.1093/annonc/mdm481 – ident: e_1_2_9_16_1 doi: 10.1148/radiol.11110469 – ident: e_1_2_9_8_1 doi: 10.1016/j.ejca.2019.12.010 – ident: e_1_2_9_29_1 doi: 10.1258/jms.2011.010086 – ident: e_1_2_9_33_1 doi: 10.1186/1741-7015-10-163 – ident: e_1_2_9_36_1 doi: 10.3310/hta4140 – ident: e_1_2_9_10_1 doi: 10.1038/bjc.2016.68 – volume-title: IARC Handbooks of Cancer Prevention year: 2016 ident: e_1_2_9_24_1 – ident: e_1_2_9_37_1 doi: 10.1186/1471-2458-13-464 |
| SSID | ssj0011504 |
| Score | 2.5876937 |
| Snippet | Currently, all European countries offer some form of breast cancer screening. Nevertheless, disparities exist in the status of implementation, attendance and... |
| SourceID | pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 406 |
| SubjectTerms | Breast cancer breast cancer mortality breast cancer mortality reduction breast cancer screening Cancer Cancer screening Cancer Therapy And Prevention Mammography Medical research Medical screening screening coverage screening guidelines |
| Title | The potential of breast cancer screening in Europe |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.33204 https://www.ncbi.nlm.nih.gov/pubmed/32683673 https://www.proquest.com/docview/2464158808 https://www.proquest.com/docview/2425593584 https://pubmed.ncbi.nlm.nih.gov/PMC7754503 |
| Volume | 148 |
| WOSCitedRecordID | wos000553429100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library - Journals customDbUrl: eissn: 1097-0215 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011504 issn: 0020-7136 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZS8NAEB5KFfHF-6gXUXzwJdo9kt3gk6hFRUVEoW9hs0mwImnp4e93JpcWFQRfQmAnZLNz706-ATg0SqE9ZLEb-bRbpSLtap5ShSNjyqRSGCPzZhPq_l53u8FDA06rf2EKfIh6w400I7fXpOAmGp18gob2Xu2xEJywQGcYE5r6NnD5UB8hYKRTQjC3XczE_ApWqM1P6kenndG3CPN7oeTXADb3QJ3Ff819CRbKwNM5KyRlGRpJtgJzd-XR-ipwFBhn0B9T9RDS9VMnonr1sWNJLoYOmhdMedHROb3MKfbw1-C5c_l0fuWWDRVcK6WQLnLL57FJmbZC2sBiRhrEBpM-L9Ho61NGUC8yDbzYi0Ti-0pG6OKFskkqFMfhdWhm_SzZBMePeWyRm4bg6anRZ2yFYYlUVPfGY9GCo2plQ1uijVPTi7ewwEnmIa5BmK9BCw5q0kEBsfET0U7FnrDUslHIpY_xB1og3YL9ehj1gw49TJb0J0RDSZPAOKsFGwU367dg6KqFr3CyaorPNQFhb0-PZL2XHIObgAO9Nn1mzuffJx5e35znN1t_J92GeU6lM23mMm8HmuPhJNmFWfs-7o2Ge7mY41V19R7MXDx2nm8_AIk3_wM |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT8JAEJ4QNOrF9wNFrcaDlwrd3XZL4sUQCSgQDphwa7bbNmJMITz8_c60pUrQxMRbkx3Cduc9O_0G4EZJifbQCkzfoWqV9F3TZRF1OFqWVJHgSolk2ITsdt3BoNYrwP3iW5gUHyIvuJFmJPaaFJwK0pUv1NDhm77jnBEY6JpAL0NSzkQvv0PAUCfDYK6amIo5C1yhKqvkP132Rish5mqn5PcINnFBjZ3_bX4XtrPQ03hIZWUPCmG8Dxud7HL9ABiKjDEezah_COlGkeFTx_rM0CQZEwMNDCa96OqMYWykVfxDeGk89utNMxupYGohuDCRXw4LVGS5mgtd05iT1gKFaZ8duujtI4vAXkRUswPb56HjSOGjk-dShxGXDJePoBiP4vAEDCdggUZ-KgKop1GfgebKCoWkzjcW8BLcLo7W0xneOI29ePdSpGTm4Rl4yRmU4DonHacgGz8RlRf88TI9m3pMOBiBoA1yS3CVL6OG0LWHisPRnGgobeIYaZXgOGVn_i8YvLrckbhZucTonIDQt5dX4uFrgsJN0IF2lV4zYfTvG_daT_Xk4fTvpJew2ex32l671X0-gy1GjTRVy7TsMhRnk3l4Duv6YzacTi4Smf8EwFwAdQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFD7IFPHF-2Veq_jgS92apE0Hvog6vI4hCr6VNElxIt3Yxd_vOW1XHVMQfCvklKY59-TkOwDHSkq0h55x44B2q2QcuiFLqMLR86RKBFdKZM0mZKsVvrw02jNwNr4Lk-NDlBtupBmZvSYFtz2T1L5QQztv-pRzRmCgs4KayFRg9vKx-XxfniJgsFOgMNddTMaCMbJQndXKlyf90VSQOV0r-T2GzZxQc-l_01-GxSL4dM5zaVmBGZuuwvxDcby-BgyFxul1h1RBhHTdxImpZn3oaJKNvoMmBtNedHZOJ3Xyffx1eG5ePV1cu0VTBVcLwYWLHAuYUYkXai50Q2NW2jAKEz_fhujvE4_gXkTS8I0fcxsEUsTo5rnUNuGS4fAGVNJuarfACQwzGjmqCKKemn0azZVnhaTaN2Z4FU7GSxvpAnGcGl-8RzlWMotwDaJsDapwVJL2cpiNn4h2x_yJCk0bREwEGIOgFQqrcFgOo47QwYdKbXdENJQ4cYy1qrCZs7P8CoavIQ8kTlZOMLokIPztyZG085rhcBN4oF-n38wY_fvEo5vbi-xh---kBzDfvmxG9zetux1YYFRJU_dcz9-FyrA_snswpz-GnUF_vxD6T_7jAYs |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+potential+of+breast+cancer+screening+in+Europe&rft.jtitle=International+journal+of+cancer&rft.au=Zielonke%2C+Nadine&rft.au=Kregting%2C+Lindy+M.&rft.au=Heijnsdijk%2C+Eveline+A.+M.&rft.au=Veerus%2C+Piret&rft.date=2021-01-15&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=148&rft.issue=2&rft.spage=406&rft.epage=418&rft_id=info:doi/10.1002%2Fijc.33204&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_ijc_33204 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon |